𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy

✍ Scribed by Kerry L. Burnstein

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
158 KB
Volume
95
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Androgen deprivation has been the standard therapy for advanced and metastatic prostate cancer for over half a century, as prostate tumors are initially dependent on androgens for growth and survival. Unfortunately, in most patients undergoing androgen ablation, relapse (recurrent tumor growth) eventually occurs. The actions of the principal androgens, testosterone and dihydrotestosterone (DHT), are mediated via androgen receptors (ARs), ligand‐activated transcription factors that belong to the nuclear receptor superfamily. Because of the presence of transcriptionally active ARs in tumors from recurrent or androgen‐independent disease, there is a heightened interest in new therapeutic paradigms that target the AR and its regulatory pathways. The regulation of AR levels is highly complex with control exerted by several pathways and in a cell‐, tissue‐, and developmental‐stage specific manner. Androgens are important regulators of AR mRNA and protein through transcriptional and post‐transcriptional mechanisms. This article reviews the evidence implicating the AR in recurrent prostate cancer and discusses the multiple mechanisms that regulate AR levels in normal and neoplastic cells. The complexity of AR regulation suggests that there will be an ample array of potential new drug targets for modulating levels of this receptor, a key signaling molecule in prostate cancer. © 2005 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Interaction of IGF signaling and the and
Interaction of IGF signaling and the androgen receptor in prostate cancer progression
✍ Jennifer D. Wu; Kathy Haugk; Libby Woodke; Peter Nelson; Ilsa Coleman; Stephen R 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 352 KB 👁 1 views

## Abstract The insulin‐like growth factor type I receptor (IGF‐IR) has been suggested to play an important role in prostate cancer progression and possibly in the progression to androgen‐independent (AI) disease. The term AI may not be entirely correct, in that recent data suggest that expression

Androgen receptor coregulators and their
Androgen receptor coregulators and their involvement in the development and progression of prostate cancer
✍ Renée Chmelar; Grant Buchanan; Eleanor F. Need; Wayne Tilley; Norman M. Greenber 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 318 KB 👁 1 views

## Abstract The androgen receptor signaling axis plays an essential role in the development, function and homeostasis of male urogenital structures including the prostate gland although the mechanism by which the AR axis contributes to the initiation, progression and metastatic spread of prostate c

5α-androstane-3α,17β-diol supports human
5α-androstane-3α,17β-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: Implication of androgen-independent prostate cancer progression
✍ Qing Yang; Mark A. Titus; Kar-Ming Fung; Hsueh-Kung Lin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 323 KB

## Abstract Androgen and androgen receptor (AR) are involved in growth of normal prostate and development of prostatic diseases including prostate cancer. Androgen deprivation therapy is used for treating advanced prostate cancer. This therapeutic approach focuses on suppressing the accumulation of

Androgen receptor: A key molecule in the
Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence
✍ Mary-Ellen Taplin; Steven P. Balk 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

## Abstract Despite earlier detection and recent advances in surgery and radiation, prostate cancer is second only to lung cancer in male cancer deaths in the United States. Hormone therapy in the form of medical or surgical castration remains the mainstay of systemic treatment in prostate cancer.